Table 1 Main information of the included studies
Author (ref.) | Publishing year | country | No. of patients | TLSs detection methods | TLSs location | Grouping methods | Follow-up (months) Median (range) | Outcome |
|---|---|---|---|---|---|---|---|---|
Figenschau et al. [15] | 2015 | Norway | 290 | IHC for T, B cells and HEV | Global | Negative/positive | NA | NA |
Kim et al. [17] | 2016 | Korea | 204 | IHC for T, B cells and HEV | Tumor adjacent tissues | None, little, moderate, or abundant | NA | NA |
Zhou et al. [18] | 2016 | China | 100 | IHC for T, B, DC cells, and HEV | Global | Negative/positive | NA | NA |
Lee et al. [19] | 2016 | Korea | 769 | IHC for T and B cells | Tumor adjacent tissues | None, little, moderate, or abundant | 47 years (23–76 years) | OS, DFS |
Laurence et al. [20] | 2017 | Belgium | 125 | IHC for T and B cells | Global | Negative/positive | NA | NA |
Gao et al. [21] | 2017 | China | 150 | IHC for T, B, DC cells, and HEV | Global | Negative/positive | NA | NA |
Liu et al. [22] | 2017 | China | 248 | IHC for T and B cells | Global | Negative/positive | 78 (1–134) | DFS |
Lee et al. [23] | 2019 | Korea | 335 | IHC for T, B cells and HEV | Tumor adjacent tissues | None, little, moderate, or abundant | NA | OS |
Chao et al. [24] | 2020 | China | 60 | IHC for T, B cells | Tumor adjacent tissues | None, little, moderate, or abundant | 48 (22–163) | DFS |